Cargando…

Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial

BACKGROUND: Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent...

Descripción completa

Detalles Bibliográficos
Autores principales: El Guerche-Séblain, Clotilde, Moureau, Annick, Schiffler, Camille, Dupuy, Martin, Pepin, Stephanie, Samson, Sandrine I., Vanhems, Philippe, Schellevis, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449994/
https://www.ncbi.nlm.nih.gov/pubmed/30947693
http://dx.doi.org/10.1186/s12879-019-3920-8
_version_ 1783408966470991872
author El Guerche-Séblain, Clotilde
Moureau, Annick
Schiffler, Camille
Dupuy, Martin
Pepin, Stephanie
Samson, Sandrine I.
Vanhems, Philippe
Schellevis, François
author_facet El Guerche-Séblain, Clotilde
Moureau, Annick
Schiffler, Camille
Dupuy, Martin
Pepin, Stephanie
Samson, Sandrine I.
Vanhems, Philippe
Schellevis, François
author_sort El Guerche-Séblain, Clotilde
collection PubMed
description BACKGROUND: Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres. METHODS: This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013–001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza. RESULTS: Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes. CONCLUSIONS: Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza. TRIAL REGISTRATION: EudraCT no. 2013–001231-51. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-019-3920-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6449994
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64499942019-04-16 Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial El Guerche-Séblain, Clotilde Moureau, Annick Schiffler, Camille Dupuy, Martin Pepin, Stephanie Samson, Sandrine I. Vanhems, Philippe Schellevis, François BMC Infect Dis Research Article BACKGROUND: Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres. METHODS: This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013–001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza. RESULTS: Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes. CONCLUSIONS: Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza. TRIAL REGISTRATION: EudraCT no. 2013–001231-51. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-019-3920-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-04 /pmc/articles/PMC6449994/ /pubmed/30947693 http://dx.doi.org/10.1186/s12879-019-3920-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
El Guerche-Séblain, Clotilde
Moureau, Annick
Schiffler, Camille
Dupuy, Martin
Pepin, Stephanie
Samson, Sandrine I.
Vanhems, Philippe
Schellevis, François
Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title_full Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title_fullStr Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title_full_unstemmed Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title_short Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
title_sort epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase iii efficacy trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449994/
https://www.ncbi.nlm.nih.gov/pubmed/30947693
http://dx.doi.org/10.1186/s12879-019-3920-8
work_keys_str_mv AT elguercheseblainclotilde epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT moureauannick epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT schifflercamille epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT dupuymartin epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT pepinstephanie epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT samsonsandrinei epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT vanhemsphilippe epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial
AT schellevisfrancois epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial